Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemprocitinib (LNK01001) in Rheumatoid Arthritis
NCT06099535Phase 2Completed
- Sponsor
- Lynk Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zemprocitinib in rheumatoid arthritis (RA), sponsored by Lynk Pharmaceuticals. Started Nov 2021; status: completed.
02
Drugs
zemprocitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06099535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099535.